In a clinical trial done by Gerstein and his associates [16] they observed that Rosiglitazone reduces the risk of progression to diabetes in subjects who had higher baseline BMI by enhancing both β cell function and adiponectin synthesis. Here, ADIPOQ is linked to diabetes mellitus.